Compare Stocks → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEAMERICAN:IGC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGCIGC Pharma$0.46+6.5%$0.00$0.25▼$0.91$30.60M1.71796,158 shs790,171 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGCIGC Pharma0.00%+9.75%+27.39%+35.49%+9.75%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGCIGC PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGCIGC PharmaN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGCIGC Pharma$910K33.63N/AN/A$0.28 per share1.64Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGCIGC Pharma-$11.51M-$0.26N/A∞N/A-1,163.24%-110.37%-93.34%N/ALatest AAEV, IGC, BRLA, and AADV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/14/2024Q3 2024IGCIGC PharmaN/A-$0.09-$0.09-$0.09N/A$0.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGCIGC PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGCIGC Pharma0.021.850.86OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGCIGC Pharma3.87%Insider OwnershipCompanyInsider OwnershipIGCIGC Pharma19.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIGCIGC Pharma6166.81 million54.12 millionNot OptionableAAEV, IGC, BRLA, and AADV HeadlinesSourceHeadlineIGC Pharma (NYSEAMERICAN:IGC) Now Covered by Analysts at StockNews.comamericanbankingnews.com - April 24 at 2:32 AMPhase II miss in PD cognitive impairment clips Sagebioworld.com - April 18 at 3:26 PMIGC Pharma (NYSEAMERICAN:IGC) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - April 18 at 2:22 AMCDC investigating reports of counterfeit or mishandled Botox injections in 9 statesmsn.com - April 17 at 8:41 AMShort Interest in IGC Pharma, Inc. (NYSEAMERICAN:IGC) Expands By 10.6%americanbankingnews.com - April 17 at 1:48 AMIGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitationbenzinga.com - April 16 at 12:42 PMIGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Twostockhouse.com - April 16 at 7:41 AMIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Twofinance.yahoo.com - April 16 at 7:41 AMIGC Pharma Inc.barrons.com - April 9 at 9:04 PMIGC Pharma Adds Advisor in Artificial Intelligencebusinesswire.com - April 9 at 9:00 AMHeadbangers Rhythm Royale Season Three Out Nowinvisioncommunity.co.uk - April 4 at 1:27 PMUzbek envoy speaks of Punjab’s economic ‘preponderance’brecorder.com - April 4 at 1:27 PMIGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Researchbenzinga.com - April 2 at 10:19 AMAll About Kyle Richards' Mom Kathleen Richardsmsn.com - March 28 at 8:37 AMIGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stockbusinesswire.com - March 26 at 3:00 PMAlzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebomsn.com - March 20 at 5:06 PMEXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Successmsn.com - March 20 at 5:06 PMIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitationfinance.yahoo.com - March 20 at 12:06 PMIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitationbusinesswire.com - March 20 at 11:00 AMIGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024businesswire.com - March 20 at 7:00 AMBelarussian FM, Union minister Piyush Goyal highlight need to create awareness on business opportunities in two countriesnews.webindia123.com - March 14 at 9:38 AMBelarusian FM talks trade, economy, SCO cooperation in Indiathehansindia.com - March 14 at 9:38 AMGoing the Last Mile (with Evidence)insights.som.yale.edu - March 13 at 2:33 PMIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipelinefinance.yahoo.com - March 12 at 5:03 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsIGC PharmaNYSEAMERICAN:IGCIGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
